Vericel Corporation ((VCEL)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vericel Corporation is spearheading a Phase 3 clinical study titled ‘A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients With Symptomatic Chondral or Osteochondral Lesions of the Talus (MASCOT)’. The study aims to establish the superiority of MACI, an autologous cultured chondrocyte treatment, over Bone Marrow Stimulation for patients aged 17 to 65 with symptomatic chondral or osteochondral defects of the ankle.
The intervention being tested is MACI, a biological treatment involving autologous cultured chondrocytes on a porcine collagen membrane. This intervention is designed to repair full-thickness cartilage defects of the talus, potentially offering a more effective solution than traditional surgical procedures like Bone Marrow Stimulation.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment outcomes. The study’s design aims to provide clear comparative data on the efficacy of MACI versus Bone Marrow Stimulation.
The study is set to begin recruitment on April 1, 2025, with the latest update submitted on August 20, 2025. These dates are crucial as they mark the initiation and ongoing progress of the study, which investors will be closely monitoring.
For investors, the outcome of this study could significantly impact Vericel’s stock performance, particularly if MACI demonstrates superior efficacy. This could enhance Vericel’s market position in the competitive field of cartilage repair technologies, potentially influencing investor sentiment positively.
The study is currently not yet recruiting, with further details available on the ClinicalTrials portal.